Advanced search
Publication Cover
Research and Reports in Urology Volume 14, 2022 - Issue
Submit an article Journal homepage
107
Views
0
CrossRef citations to date
0
Altmetric
Short Report

Plasma Chemokine C-C Motif Ligand 2 as a Potential Biomarker for Prostate Cancer

Martin Lund1 Department of Urology, Odense University Hospital, Odense, DenmarkORCID Iconhttps://orcid.org/0000-0003-4443-8015
ORCID Icon,
Torben B Pedersen1 Department of Urology, Odense University Hospital, Odense, DenmarkORCID Iconhttps://orcid.org/0000-0003-3266-1877
ORCID Icon,
Søren Feddersen2 Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark;3 Department of Clinical Research, University of Southern Denmark, Odense, Denmark
,
Louise D Østergaard1 Department of Urology, Odense University Hospital, Odense, Denmark;3 Department of Clinical Research, University of Southern Denmark, Odense, DenmarkORCID Iconhttps://orcid.org/0000-0001-5981-367X
ORCID Icon,
Charlotte A Poulsen1 Department of Urology, Odense University Hospital, Odense, Denmark
,
Christian Enggaard2 Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark
,
Mads H A Poulsen1 Department of Urology, Odense University Hospital, Odense, Denmark;3 Department of Clinical Research, University of Southern Denmark, Odense, DenmarkORCID Iconhttps://orcid.org/0000-0002-7622-8402
ORCID Icon &
Lars Lund1 Department of Urology, Odense University Hospital, Odense, Denmark;3 Department of Clinical Research, University of Southern Denmark, Odense, DenmarkCorrespondence[email protected]
 show all
Pages 33-38 | Published online: 11 Feb 2022

References

  • Taitt HE. Global Trends and Prostate Cancer: a Review of Incidence, Detection, and Mortality as Influenced by Race, Ethnicity, and Geographic Location. Am J Mens Health. 2018;12(6):1807–1823. doi:10.1177/1557988318798279
  • Tsuzuki S, Park SH, Eber MR, Peters CM, Shiozawa Y. Skeletal complications in cancer patients with bone metastases. Int J Urol. 2016;23(10):825–832.
  • Adekoya TO, Richardson RM. Cytokines and Chemokines as Mediators of Prostate Cancer Metastasis. Int J Mol Sci. 2020;21(12):4449.
  • Gong D, Wang Y, Wang Y, et al. Extensive serum cytokine analysis in patients with prostate cancer. Cytokine. 2020;125:154810.
  • Tsaur I, Noack A, Makarevic J, et al. CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: a Pilot Study. Cancer Res Treat. 2015;47(2):306–312.
  • Roca H, Varsos Z, Pienta KJ. CCL2 Protects Prostate Cancer PC3 Cells from Autophagic Death via Phosphatidylinositol 3-Kinase/AKT-dependent Survivin Up-regulation. J Biol Chem. 2008;283(36):25057–25073.
  • Qian DZ, Rademacher BLS, Pittsenbarger J, et al. CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity. Prostate. 2010;70(4):433–442.
  • Loberg RD, Tantivejkul K, Craig M, Neeley CK, Pienta KJ. PAR1-mediated RhoA activation facilitates CCL2-induced chemotaxis in PC-3 cells. J Cell Biochem. 2007;101(5):1292–1300.
  • Lin T-H, Liu -H-H, Tsai T-H, et al. CCL2 increases αvβ3 integrin expression and subsequently promotes prostate cancer migration. Biochimica et Biophysica Acta. 2013;1830(10):4917–4927.
  • Tsaur I, Rutz J, Makarević J, et al. CCL2 promotes integrin-mediated adhesion of prostate cancer cells in vitro. World J Urol. 2015;33(7):1051–1056.
  • Loberg RD, Ying C, Craig M, et al. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res. 2007;67(19):9417–9424.
  • Zhang J, Patel L, Pienta KJ. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev. 2010;21(1):41–48.
  • Izhak L, Wildbaum G, Weinberg U, et al. Predominant expression of CCL2 at the tumor site of prostate cancer patients directs a selective loss of immunological tolerance to CCL2 that could be amplified in a beneficial manner. J Immunol. 2010;184(2):1092–1101.
  • Pienta KJ, Machiels J-P, Schrijvers D, et al. Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. Invest New Drugs. 2013;31(3):760–768.
  • Izumi K, Mizokami A, Lin HP, et al. Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer. Oncotarget. 2016;7(7):8389–8398.
  • Natsagdorj A, Izumi K, Hiratsuka K, et al. CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells. Cancer Sci. 2019;110(1):279–288.
  • Ahmad AE, Mohammed A, Bhindi B, et al. Serum Adipokines as Predictors for the Outcome of Prostate Biopsies at Early Stage Prostate Cancer Diagnosis. Cancer Manag Res. 2019;11:10043–10050.
  • Rosenberg-Hasson Y, Hansmann L, Liedtke M, Herschmann I, Maecker HT. Effects of serum and plasma matrices on multiplex immunoassays. Immunol Res. 2014;58(2):224–233.
  • Tukey JW. Exploratory data analysis: reading, Mass. 1977.
  • Merlano MC, Abbona A, Paccagnella M, et al. Cytokine Profiling of End Stage Cancer Patients Treated with Immunotherapy. Vaccines. 2021;9(3):764.
  • Sun X, Ye D, Du L, Qian Y, Jiang X, Mao Y. Genetically predicted levels of circulating cytokines and prostate cancer risk: a Mendelian randomization study. Int J Cancer. 2020;147(9):2469–2478.
  • Lu Y, Cai Z, Xiao G, et al. CCR2 expression correlates with prostate cancer progression. J Cell Biochem. 2007;101(3):676–685.
  • Roca H, Varsos ZS, Sud S, Craig MJ, Ying C, Pienta KJ. CCL2 and Interleukin-6 Promote Survival of Human CD11b+ Peripheral Blood Mononuclear Cells and Induce M2-type Macrophage Polarization. J Biol Chem. 2009;284(49):34342–34354.
  • Tsai Y-C, Chen W-Y, Abou-Kheir W, et al. Androgen deprivation therapy-induced epithelial-mesenchymal transition of prostate cancer through downregulating SPDEF and activating CCL2. Biochim Biophys Acta Mol Basis Dis. 2018;1864(5 Pt A):1717–1727.
  • Salvi S, Bandini E, Carloni S, et al. Detection and Investigation of Extracellular Vesicles in Serum and Urine Supernatant of Prostate Cancer Patients. Diagnostics. 2021;11(3):466.
  • Tosun H, Demirtaş A, Sönmez G, Tombul ŞT, Akalın H, Özkul Y. Can the expression level of PIWIL 2 gene be a serum marker for prostate cancer? A single-center prospective study. Turk J Urol. 2019;45(Supp. 1):S22–s5.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.